An Expanded Clinical Study Evaluating the AAV2-RPE65 Gene Therapy(LX101) in Patients With LCA

NCT06024057 · clinicaltrials.gov ↗

NA

Phase

NOT_YET_RECRUITING

Status

3

Enrollment

OTHER

Sponsor class

Conditions

To Evaluate the Scaling Clinical Study of AAV2-RPE65 Gene Therapy Agent (LX101) in Patients With Congenital Amaurosis (LCA)

Interventions

DRUG: LX101

Sponsor

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine